Cutaneous T cell lymphoma: Difference between revisions
No edit summary |
|||
| Line 8: | Line 8: | ||
==[[Overview]]== | ==[[Overview]]== | ||
'''Cutaneous T-Cell lymphoma''' (CTCL) is a class of [[non-Hodgkin's lymphoma]], which is a type of [[cancer]] of the [[immune system]]. Cutaneous T-cell [[Lymphomas|lymphoma]] (CTCL) is infiltration of malignant T cells and activated T cells in the skin. Cutaneous T cell lymphoma arises from [[T-cell]] lymphocytes, which are normally involved in the [[Cell (biology)|cell]] mediated [[immune]] response. The [[malignant]] T cells in the [[body]] are pushed to the [[Surface area|surface]] of the [[skin]] in a [[biological]] process used to rid the [[body]] of offending material, causing various [[lesion]]s to appear on the [[skin]]. These [[lesions]] change shape as the [[disease]] progresses, typically beginning as what appears to be a [[rash]] and eventually forming [[Plaque|plaques]] and [[tumor]]s before [[metastasis|metastatizing]] to other parts of the [[Human body|body]]. There are 3 classification methods used to classify cutaneous T cell lymphoma into several subtypes. Mycosis Fungoides was first described in 1806 by French dermatologist [[Jean-Louis-Marc Alibert]]. Sezary's disease was first described by Albert Sézary. On [[microscopic]] [[histopathological]] [[analysis]], atypical [[lymphoid]] [[Cell (biology)|cells]], [[polymorphous]] [[inflammatory]] infiltrate in the dermis, and [[lymphocytes]] with cerebroid [[nuclei]] are characteristic findings of mycosis fungoides. Cutaneous T cell lymphoma is caused by a [[mutation]] in the T cells. Cutaneous T cell lymphoma must be differentiated from other [[Disease|diseases]] such as [[eczema]] and [[psoriasis]]. Mycosis fungoides commonly affects 45 and 55 years. [[Sézary syndrome]] commonly affects 60 years. In the United States, [[Male|males]] are more commonly affected with cutaneous T cell lymphoma than [[Female|females]]. In the United States, cutaneous T cell lymphoma usually affects individuals of the African American [[race]].There are no established risk factors for cutaneous T cell lymphoma. If left untreated, cutaneous T cell lymphoma may progress to develop patches , plaque, and tumors. Depending on the extent of the lymphoma at the time of diagnosis, the prognosis may vary. According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for cutaneous T cell lymphoma.The staging of cutaneous T cell lymphoma is based on skin and lymph node involvement.The most common symptoms of cutaneous T cell lymphoma include [[fever]], [[weight loss]], [[skin]] [[rash]], [[night sweats]], [[itching]], [[Chest pain|chest pain,]] [[abdominal pain]], and [[bone pain]]. Common [[Physical examination|physical]] [[Physical examination|examination]] findings of cutaneous T cell lymphoma include [[fever]], [[rash]], [[pruritus]], [[ulcer]], [[chest]] [[Tenderness (medicine)|tenderness]], [[Abdomen|abdominal]] [[Tenderness (medicine)|tenderness]], [[bone]] [[tenderness]], [[Lymphadenopathy|peripheral lymphadenopathy]], and [[Lymphadenopathy|central lymphadenopathy]].[[Medical laboratory|Laboratory]] tests for cutaneous T cell lymphoma include [[complete blood count]] ([[CBC]]), [[blood]] [[chemistry]] studies, [[flow cytometry]], [[immunohistochemistry]], and [[immunophenotyping]]. The definitive diagnosis of cutaneous T cell lymphoma is confirmed by either a [[skin]] [[biopsy]] or a [[lymph node]] [[biopsy]]. CT scan may be helpful in the diagnosis of cutaneous T cell lymphoma. MRI may be helpful in the diagnosis of cutaneous T cell lymphoma. [[PET]] scan may be helpful in the [[diagnosis]] of cutaneous T cell lymphoma.Other diagnostic studies for cutaneous T cell lymphoma include [[bone marrow aspiration]] and [[bone marrow biopsy]].The predominant [[therapy]] for cutaneous T cell lymphoma is [[PUVA]]. Adjunctive [[chemotherapy]], [[radiotherapy]], [[biological therapy]], [[retinoid]] [[therapy]], and photophoresis may be required | |||
==[[Classification]]== | ==[[Classification]]== | ||
Revision as of 17:45, 26 December 2018
For patient information, click here
|
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Synonyms and keywords: CTCL; Mycosis fungoides; Sezary syndrome; Sezary's disease; Alibert-Bazin syndrome; Granuloma fungoides
Overview
Cutaneous T-Cell lymphoma (CTCL) is a class of non-Hodgkin's lymphoma, which is a type of cancer of the immune system. Cutaneous T-cell lymphoma (CTCL) is infiltration of malignant T cells and activated T cells in the skin. Cutaneous T cell lymphoma arises from T-cell lymphocytes, which are normally involved in the cell mediated immune response. The malignant T cells in the body are pushed to the surface of the skin in a biological process used to rid the body of offending material, causing various lesions to appear on the skin. These lesions change shape as the disease progresses, typically beginning as what appears to be a rash and eventually forming plaques and tumors before metastatizing to other parts of the body. There are 3 classification methods used to classify cutaneous T cell lymphoma into several subtypes. Mycosis Fungoides was first described in 1806 by French dermatologist Jean-Louis-Marc Alibert. Sezary's disease was first described by Albert Sézary. On microscopic histopathological analysis, atypical lymphoid cells, polymorphous inflammatory infiltrate in the dermis, and lymphocytes with cerebroid nuclei are characteristic findings of mycosis fungoides. Cutaneous T cell lymphoma is caused by a mutation in the T cells. Cutaneous T cell lymphoma must be differentiated from other diseases such as eczema and psoriasis. Mycosis fungoides commonly affects 45 and 55 years. Sézary syndrome commonly affects 60 years. In the United States, males are more commonly affected with cutaneous T cell lymphoma than females. In the United States, cutaneous T cell lymphoma usually affects individuals of the African American race.There are no established risk factors for cutaneous T cell lymphoma. If left untreated, cutaneous T cell lymphoma may progress to develop patches , plaque, and tumors. Depending on the extent of the lymphoma at the time of diagnosis, the prognosis may vary. According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for cutaneous T cell lymphoma.The staging of cutaneous T cell lymphoma is based on skin and lymph node involvement.The most common symptoms of cutaneous T cell lymphoma include fever, weight loss, skin rash, night sweats, itching, chest pain, abdominal pain, and bone pain. Common physical examination findings of cutaneous T cell lymphoma include fever, rash, pruritus, ulcer, chest tenderness, abdominal tenderness, bone tenderness, peripheral lymphadenopathy, and central lymphadenopathy.Laboratory tests for cutaneous T cell lymphoma include complete blood count (CBC), blood chemistry studies, flow cytometry, immunohistochemistry, and immunophenotyping. The definitive diagnosis of cutaneous T cell lymphoma is confirmed by either a skin biopsy or a lymph node biopsy. CT scan may be helpful in the diagnosis of cutaneous T cell lymphoma. MRI may be helpful in the diagnosis of cutaneous T cell lymphoma. PET scan may be helpful in the diagnosis of cutaneous T cell lymphoma.Other diagnostic studies for cutaneous T cell lymphoma include bone marrow aspiration and bone marrow biopsy.The predominant therapy for cutaneous T cell lymphoma is PUVA. Adjunctive chemotherapy, radiotherapy, biological therapy, retinoid therapy, and photophoresis may be required